Myriad Genetics Expands Precise MRD Test Availability for Cancer Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Newsfilter
- Market Expansion: Myriad Genetics announces the expansion of the Precise MRD test to breast, colorectal, and renal cancer patients, increasing access for over 6 million cancer patients in the U.S., significantly enhancing the company's market share in precision medicine.
- Clinical Validity Support: Results from the MONITOR-Breast study show that Precise MRD monitoring in breast cancer patients achieved a 93% baseline detection rate and demonstrated 100% specificity in predicting treatment response, further solidifying its importance in cancer management.
- Risk Stratification Capability: The study found that patients who were ctDNA positive after neoadjuvant therapy were 47 times more likely to remain ctDNA positive post-surgery, highlighting the test's potential value in personalized treatment decisions and identifying high-risk patients.
- Continuous Monitoring Advantage: Longitudinal testing revealed that 78% of patients achieved ctDNA clearance, underscoring the critical role of continuous monitoring in improving patient outcomes and aiding clinicians in adjusting treatment plans to address varying disease progressions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MYGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MYGN
Wall Street analysts forecast MYGN stock price to rise
5 Analyst Rating
2 Buy
2 Hold
1 Sell
Hold
Current: 4.630
Low
4.00
Averages
7.38
High
9.00
Current: 4.630
Low
4.00
Averages
7.38
High
9.00
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Illumina Appoints New Board Member
- New Board Appointment: Illumina announced the appointment of Daniel M. Skovronsky to its Board of Directors, effective June 16, 2026, with his extensive experience in drug discovery and clinical development expected to provide strategic advantages for the company.
- Industry Background: Skovronsky currently serves as Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories, and his expertise is anticipated to aid Illumina's further development in the biotechnology sector.
- Previous Roles: Prior to this, Skovronsky was a board member at Myriad Genetics and founded Avid Radiopharmaceuticals in 2004, serving as CEO, showcasing his deep roots in the biopharmaceutical industry.
- Stock Performance: Illumina closed Tuesday's trading at $164.93, up 2.20%, and this positive market reaction may be linked to the strategic significance of the new appointment, reflecting investor confidence in the company's future growth.
See More
Myriad Genetics Expands Precise MRD Test Availability for Cancer Patients
- Market Expansion: Myriad Genetics announces the expansion of the Precise MRD test to breast, colorectal, and renal cancer patients, increasing access for over 6 million cancer patients in the U.S., significantly enhancing the company's market share in precision medicine.
- Clinical Validity Support: Results from the MONITOR-Breast study show that Precise MRD monitoring in breast cancer patients achieved a 93% baseline detection rate and demonstrated 100% specificity in predicting treatment response, further solidifying its importance in cancer management.
- Risk Stratification Capability: The study found that patients who were ctDNA positive after neoadjuvant therapy were 47 times more likely to remain ctDNA positive post-surgery, highlighting the test's potential value in personalized treatment decisions and identifying high-risk patients.
- Continuous Monitoring Advantage: Longitudinal testing revealed that 78% of patients achieved ctDNA clearance, underscoring the critical role of continuous monitoring in improving patient outcomes and aiding clinicians in adjusting treatment plans to address varying disease progressions.
See More
Myriad Genetics Appoints New Chief Technology Officer
- New CTO Appointment: Myriad Genetics appointed Raj Jampa as Chief Technology Officer effective June 1, 2026, aiming to leverage his technology leadership to scale business operations and accelerate innovation, thereby enhancing customer experience and supporting growth strategies.
- Technology Strategy Execution: Jampa will oversee the strategy and execution of Myriad's technology organization, particularly focusing on leveraging AI to drive efficiency and effectiveness, which will directly impact the company's operational model and market competitiveness.
- Rich Industry Experience: Prior to joining Myriad, Jampa held senior technology leadership roles at Agilent Technologies, Exact Sciences, and Genomic Health, where he successfully led large-scale transformation initiatives, indicating his capability to modernize technology infrastructure and advance Myriad's growth strategy.
- Forward-Looking Statements: Myriad Genetics stated that Jampa's leadership will be crucial in strengthening the digital technology foundation, enhancing customer experience, and supporting the next phase of growth and value creation, reflecting the company's positive outlook on future developments.
See More
Myriad Genetics Unveils New Data on MRD Testing Across Cancer Types
- Clinical Data Showcase: Myriad Genetics will present data from six poster sessions demonstrating the utility of its Precise MRD™ test across various cancer types, particularly highlighting a 97% baseline detection rate from the MONSTAR-SCREEN-3 study, underscoring the test's significance in early cancer recurrence risk assessment.
- Ultra-Sensitive Detection Advantage: The study reveals that patients who were ctDNA-positive one month post-surgery had significantly worse disease-free survival compared to ctDNA-negative patients, emphasizing the potential value of ultra-sensitive ctDNA detection in clinical decision-making and possibly paving the way for new detection standards.
- Applicability Across Cancer Types: Myriad's research spans ovarian, gastric, head and neck cancers, and sarcoma, showcasing the clinical utility of ctDNA as a biomarker for recurrence and therapy response, further solidifying its role in precision medicine.
- Industry Expert Interaction: Myriad will offer attendees the opportunity to engage with Chief Scientific Officer Dale Muzzey during the conference, providing insights into the technical details of the Precise MRD test and its clinical evidence across multiple solid tumors, fostering knowledge sharing and collaboration within the industry.
See More
Myriad Genetics Launches Prolaris + AI Test for Prostate Cancer Prognosis
- New Test Launch: Myriad Genetics has announced the launch of the Prolaris + AI test, designed to enhance the accuracy of prostate cancer prognosis prediction by integrating clinical-pathological features with AI digital pathology technology, expected to be available by the end of May 2026.
- Strong Market Demand: With over 300,000 new prostate cancer cases diagnosed annually in the U.S., early treatment is crucial for survival, making this test a timely solution to meet the urgent need for precision medicine and assist physicians in developing more effective monitoring strategies.
- Technological Innovation: The test leverages PATHOMIQ AI technology to provide a clinical cell-cycle risk (CCR) score and utilizes an AI model to predict the likelihood of higher Gleason scores at subsequent check-ups, thereby enhancing the guidance capabilities of existing pathology tools.
- Validation Study Support: The AI model, trained on biopsy histopathology images from 998 patients and validated in 296 patients, demonstrated that the AI-Gleason Upgrade Risk (AI-GUR) is a statistically significant independent predictor of Gleason score upgrades, further enhancing the test's efficacy.
See More
Identifying Potentially Profitable Stocks
- Impinj Risk Analysis: Impinj (PI) has a trailing 12-month GAAP operating margin of -1.8%, with projected sales growth of only 9.3% over the next year indicating sluggish demand, and its forward P/E ratio of 64.7 suggests overvaluation, posing a risk of value destruction for investors.
- Myriad Genetics Financial Struggles: Myriad Genetics (MYGN) reports a GAAP operating margin of -46.9% over the past year, with annual revenue growth of just 3.5%, significantly below healthcare sector standards, and negative returns on capital indicate management's failure to generate profits while expanding, warranting caution from investors.
- Gevo Growth Potential: Gevo (GEVO) has achieved an impressive 19% annual revenue growth over the past decade, despite a GAAP operating margin of -2.9%, as its EBITDA profits and efficiency have improved due to fixed cost leverage, highlighting its competitive position in the renewable fuel market.
- Market Watch Recommendations: While Impinj and Myriad Genetics face significant challenges, Gevo's performance suggests potential long-term growth opportunities, making it a stock to watch for investors interested in sustainable aviation fuel market share expansion.
See More
Illumina Appoints New Board Member
- New Board Appointment: Illumina announced the appointment of Daniel M. Skovronsky to its Board of Directors, effective June 16, 2026, with his extensive experience in drug discovery and clinical development expected to provide strategic advantages for the company.
- Industry Background: Skovronsky currently serves as Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories, and his expertise is anticipated to aid Illumina's further development in the biotechnology sector.
- Previous Roles: Prior to this, Skovronsky was a board member at Myriad Genetics and founded Avid Radiopharmaceuticals in 2004, serving as CEO, showcasing his deep roots in the biopharmaceutical industry.
- Stock Performance: Illumina closed Tuesday's trading at $164.93, up 2.20%, and this positive market reaction may be linked to the strategic significance of the new appointment, reflecting investor confidence in the company's future growth.
See More
Myriad Genetics Expands Precise MRD Test Availability for Cancer Patients
- Market Expansion: Myriad Genetics announces the expansion of the Precise MRD test to breast, colorectal, and renal cancer patients, increasing access for over 6 million cancer patients in the U.S., significantly enhancing the company's market share in precision medicine.
- Clinical Validity Support: Results from the MONITOR-Breast study show that Precise MRD monitoring in breast cancer patients achieved a 93% baseline detection rate and demonstrated 100% specificity in predicting treatment response, further solidifying its importance in cancer management.
- Risk Stratification Capability: The study found that patients who were ctDNA positive after neoadjuvant therapy were 47 times more likely to remain ctDNA positive post-surgery, highlighting the test's potential value in personalized treatment decisions and identifying high-risk patients.
- Continuous Monitoring Advantage: Longitudinal testing revealed that 78% of patients achieved ctDNA clearance, underscoring the critical role of continuous monitoring in improving patient outcomes and aiding clinicians in adjusting treatment plans to address varying disease progressions.
See More
Myriad Genetics Appoints New Chief Technology Officer
- New CTO Appointment: Myriad Genetics appointed Raj Jampa as Chief Technology Officer effective June 1, 2026, aiming to leverage his technology leadership to scale business operations and accelerate innovation, thereby enhancing customer experience and supporting growth strategies.
- Technology Strategy Execution: Jampa will oversee the strategy and execution of Myriad's technology organization, particularly focusing on leveraging AI to drive efficiency and effectiveness, which will directly impact the company's operational model and market competitiveness.
- Rich Industry Experience: Prior to joining Myriad, Jampa held senior technology leadership roles at Agilent Technologies, Exact Sciences, and Genomic Health, where he successfully led large-scale transformation initiatives, indicating his capability to modernize technology infrastructure and advance Myriad's growth strategy.
- Forward-Looking Statements: Myriad Genetics stated that Jampa's leadership will be crucial in strengthening the digital technology foundation, enhancing customer experience, and supporting the next phase of growth and value creation, reflecting the company's positive outlook on future developments.
See More
Myriad Genetics Unveils New Data on MRD Testing Across Cancer Types
- Clinical Data Showcase: Myriad Genetics will present data from six poster sessions demonstrating the utility of its Precise MRD™ test across various cancer types, particularly highlighting a 97% baseline detection rate from the MONSTAR-SCREEN-3 study, underscoring the test's significance in early cancer recurrence risk assessment.
- Ultra-Sensitive Detection Advantage: The study reveals that patients who were ctDNA-positive one month post-surgery had significantly worse disease-free survival compared to ctDNA-negative patients, emphasizing the potential value of ultra-sensitive ctDNA detection in clinical decision-making and possibly paving the way for new detection standards.
- Applicability Across Cancer Types: Myriad's research spans ovarian, gastric, head and neck cancers, and sarcoma, showcasing the clinical utility of ctDNA as a biomarker for recurrence and therapy response, further solidifying its role in precision medicine.
- Industry Expert Interaction: Myriad will offer attendees the opportunity to engage with Chief Scientific Officer Dale Muzzey during the conference, providing insights into the technical details of the Precise MRD test and its clinical evidence across multiple solid tumors, fostering knowledge sharing and collaboration within the industry.
See More
Myriad Genetics Launches Prolaris + AI Test for Prostate Cancer Prognosis
- New Test Launch: Myriad Genetics has announced the launch of the Prolaris + AI test, designed to enhance the accuracy of prostate cancer prognosis prediction by integrating clinical-pathological features with AI digital pathology technology, expected to be available by the end of May 2026.
- Strong Market Demand: With over 300,000 new prostate cancer cases diagnosed annually in the U.S., early treatment is crucial for survival, making this test a timely solution to meet the urgent need for precision medicine and assist physicians in developing more effective monitoring strategies.
- Technological Innovation: The test leverages PATHOMIQ AI technology to provide a clinical cell-cycle risk (CCR) score and utilizes an AI model to predict the likelihood of higher Gleason scores at subsequent check-ups, thereby enhancing the guidance capabilities of existing pathology tools.
- Validation Study Support: The AI model, trained on biopsy histopathology images from 998 patients and validated in 296 patients, demonstrated that the AI-Gleason Upgrade Risk (AI-GUR) is a statistically significant independent predictor of Gleason score upgrades, further enhancing the test's efficacy.
See More
Identifying Potentially Profitable Stocks
- Impinj Risk Analysis: Impinj (PI) has a trailing 12-month GAAP operating margin of -1.8%, with projected sales growth of only 9.3% over the next year indicating sluggish demand, and its forward P/E ratio of 64.7 suggests overvaluation, posing a risk of value destruction for investors.
- Myriad Genetics Financial Struggles: Myriad Genetics (MYGN) reports a GAAP operating margin of -46.9% over the past year, with annual revenue growth of just 3.5%, significantly below healthcare sector standards, and negative returns on capital indicate management's failure to generate profits while expanding, warranting caution from investors.
- Gevo Growth Potential: Gevo (GEVO) has achieved an impressive 19% annual revenue growth over the past decade, despite a GAAP operating margin of -2.9%, as its EBITDA profits and efficiency have improved due to fixed cost leverage, highlighting its competitive position in the renewable fuel market.
- Market Watch Recommendations: While Impinj and Myriad Genetics face significant challenges, Gevo's performance suggests potential long-term growth opportunities, making it a stock to watch for investors interested in sustainable aviation fuel market share expansion.
See More
